Clinical Specialty Index

The guideline introduces significant updates in blood pressure management and anticoagulation reversal strategies for ICH.

Tirzepatide delivers unprecedented weight loss results in obesity management.

GINA 2021 formalizes ICS-formoterol as the preferred reliever across all adult/adolescent steps and adds new pediatric and Step 5 options.

CHEST provides comprehensive updates emphasizing DOAC use for VTE management without cancer.

Finerenone reduces cardiovascular events in diabetes with kidney disease.

Finerenone reduces kidney and cardiovascular risks in diabetes patients.

LAAC proves noninferior to DOACs in high-risk AF stroke prevention.

The latest vancomycin guidelines prioritize AUC-guided monitoring over traditional trough levels for MRSA infections.

Alteplase shows promise for late-presenting stroke when guided by imaging.

Andexanet alfa reduces factor Xa activity by 92% in bleeding emergencies.

MRI-guided thrombolysis may benefit stroke of unknown onset.

The 2016 ATS/IDSA update reshapes empiric antibiotic selection, de-escalation, and duration of therapy for hospital-acquired and ventilator-associated pneumonia around local resistance data and pharmacokinetic optimization.

This systematic review of observational data confirms that continuous subcutaneous levodopa infusions reduce motor fluctuations in advanced Parkinson disease, with infusion-site reactions as the dominant tolerability concern pharmacists must proactively manage.

ACHIEVE-5 provides the first phase 3 evidence that an oral nonpeptide GLP-1 receptor agonist can be layered onto titrated basal insulin to add glycemic and weight benefit without excess hypoglycemia.